My cancer is in remission – does this mean I'm cured?

May 18, 2018 by Ian Olver, The Conversation
We only know if a cancer has been cured in hindsight. Credit: Kaylee Eden on Unsplash

So you've been through cancer treatment and your doctor has called you in for "some good news". Satisfied, she tells you your cancer is "in remission."

What does this mean? Are you cured? Is the gone forever? And what about all those stories you've heard of someone who thought they'd "won the battle" – but then their cancer came back?

Detecting cancer

Your cancer is in complete when, after , no cancer can be detected. The term "cure" can only be used in hindsight. Commonly, years after the cancer has gone into remission, if it has not returned (or relapsed), it is said to have been cured.

However, a secondary cancer could occur if the same conditions that triggered the first are present.

When a cancer can no longer be detected, it's cured only if the treatment has killed every cancer cell. But it's difficult to know if that's the case due to our inability to detect small amounts of cancer.

A skilled specialist may be able to feel a breast lump that is half-a-centimetre wide. A plain chest X-ray can be expected to detect cancers from 1cm wide. And a CT scan will detect smaller cancers to a few millimetres.

But a cancer 1cm across on a scan has about 100 million cancer cells; even a 0.5cm cancer has about 10 million . A 1mm cancer, which would not show up on scans, has 100,000 .

So, even when a cancer can no longer be seen and is no longer causing symptoms, there can still be millions of cells remaining. They can keep growing and eventually the cancer will be large enough to be detected again. That's when the cancer is said to have relapsed.

We don’t always know if all the cancer cells have been killed. Credit:

Some cancers, like testicular cancer, produce proteins (alpha FP and Beta HCG) that can be measured in blood. Measuring these is more accurate than scans in detecting small amounts of cancer.

Better still, chronic myeloid leukaemia (CML) – a rare form of leukaemia – has a characteristic genetic abnormality, which a very sensitive blood test can detect. This is helpful in determining whether a treatment has eradicated microscopic disease. The holy grail would be to develop such sensitive blood tests for every cancer.

Additional therapies

Because we can't tell whether remission means cure for most cancers, treatment strategies have been devised to increase the likelihood of cure. If a cancer is being treated with chemotherapy and becomes undetectable, further courses will be given to continue to reduce the remaining microscopic disease.

Some cancers, like breast and bowel cancer, where there is no visible disease after surgery, are given additional treatment in case some cells are still present near the operation site or have spread more widely through the bloodstream. Radiotherapy is given after the cancer has been removed by surgery to kill any remaining cells in the breast.

When it comes to brain cancer, it's difficult to know if it has been completely cleared. The extent of surgery is limited because of the damage to normal tissues and function, and we don't have very effective therapies to follow up the surgery. This is why it's so difficult to cure.

Chemotherapy, hormone therapy (for breast cancer) or both are given to kill any cells that might have escaped to more distant sites. Although we can't see the cancer shrinking with the additional (adjunct) treatment, we know from trials comparing patients who receive additional treatment with those who do not that the additional treatment results in more patients being cured.

It is common to use multiple types of treatment – surgery, radiotherapy or drug therapy – to improve the chances of a cure.

Chemotherapy may not be able to kill all of a cancer because it kills cells only when they are dividing, which means resting cells escape. Only a percentage of cells are dividing at any one time. In cancer that percentage is higher than in most normal tissues, so cancer suffers more damage than normal tissues with chemotherapy. Multiple doses might catch the resting cells when they begin to divide.

Chemotherapy, hormone therapy or both are given to kill any cells that might have escaped to more distant sites. Credit:

Another problem is that, after initially shrinking some of the cancer, some cells are found to be resistant, or become resistant, to the chemotherapy and are left untreated. Drug combinations are given as cells resistant to one drug might be susceptible to another.

Five-year outcomes

It's common when reporting cancer outcomes to compare the five-year survival rate, which is the percentage of patients who survive five years after diagnosis. Five years is a convenient interval at which everyone can collect statistics so comparisons can be made between cancers – or the outcomes of cancers between treatment centres, states or countries.

As it happens, with many cancers in remission, to have survived five years does mean they are probably cured. But there are differences for different cancer types.

A person diagnosed with an aggressive lymphoma whose cancer achieves remission is most likely to have been cured if the cancer has not returned in two years. This is because any residual lymphoma would be expected to regrow rapidly.

The opposite is the case for breast cancer. Although the chance of relapse after complete remission is greatest in the first two years and becomes smaller over time, and the five-year survival rate is 90%, relapses have been recorded up to 20 years later.

It is important to note, though, that survival rates have greatly improved over time and are always improving. In the 1970s, only one cancer patient in three made it through the first five years after diagnosis. Today, this figure is around 70%, and exceeds 85% for some cancers that were previously fatal.

So, remission might mean cure but we only know that over time.

Explore further: Two drugs are better than one in fight against leukaemia

Related Stories

Two drugs are better than one in fight against leukaemia

March 8, 2018
Adelaide scientists have devised a way to enhance the effectiveness of a patient's leukaemia treatment by using a combination of drugs.

Genetic targets to chemo-resistant breast cancer identified

October 3, 2017
Research led by Dr. Carlos Arteaga, Director of the Harold C. Simmons Comprehensive Cancer Center, has identified potential targets for treatment of triple negative breast cancer, the most aggressive form of breast cancer.

Potential therapy identified for aggressive breast cancer

January 25, 2018
The European Cancer Stem Cell Research Institute, based with Cardiff University, has repurposed a current cancer therapy, TRAIL, to find a new treatment for advanced cancers that are resistant to anti-hormone therapy.

CAR-T immunotherapy now approved for certain adult lymphoma patients

October 20, 2017
The Food and Drug Administration (FDA) has approved a breakthrough cancer therapy known as CAR-T for use in adults with advanced lymphoma. The therapy uses a patient's own white blood cells, which are modified in a lab and re-trained ...

Cancer patients diagnosed early are more likely to avoid chemotherapy

October 26, 2017
Cancer patients are around five times more likely to have surgery to remove their tumour, and less likely to have chemotherapy, if they are diagnosed at the earliest stage compared to the latest stage, according to new figures.

Could viruses take cancer immunotherapy to the next level?

January 3, 2018
Immunotherapy, which helps the body's immune system attack cancer, has revolutionized treatment for cancers such as melanoma and leukemia. However, many other kinds of cancer remain resistant. A new study led by researchers ...

Recommended for you

Revealing the molecular mystery of human liver cells

October 22, 2018
A map of the cells in the human liver has been created by University Health Network Transplant Program and University of Toronto researchers, revealing for the first time differences between individual cells at the molecular ...

New tool gives deeper understanding of glioblastoma

October 22, 2018
Researchers in the lab of Charles Danko at the Baker Institute for Animal Health have developed a new tool to study genetic "switches" active in glioblastoma tumors that drive growth of the cancer. In a new paper in Nature ...

RNA thought to spread cancer shows ability to suppress breast cancer metastasis

October 22, 2018
Researchers at The University of Texas MD Anderson Cancer Center have discovered that a form of RNA called metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) appears to suppress breast cancer metastasis in mice, ...

Targeting a hunger hormone to treat obesity

October 22, 2018
About 64 per cent of Canadian adults are overweight or obese, according to Health Canada. That's a problem, because obesity promotes the emergence of chronic diseases such as type 2 diabetes, heart disease and some cancers.

New drug combination destroys chemo-resistant blood cancer

October 22, 2018
Researchers from The Ottawa Hospital and the University of Ottawa have developed a promising targeted strategy to treat chemotherapy-resistant acute myeloid leukemia (AML) and a diagnostic test to determine which AML patients ...

Major trial shows targeted drug extends breast cancer survival

October 22, 2018
Combining a targeted drug with hormone therapy substantially extends survival for women with advanced breast cancer, a major clinical trial has found.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.